The Future of CLL Treatment
- Treatment for chronic lymphocytic leukemia (CLL) has changed dramatically over the past decade, largely driven by a pivot to using targeted therapies instead of chemotherapy. This has allowed patients to live longer with better quality of life.
- Researchers continue to look for better ways to manage the chronic disease. One area of active research is whether newer medications, like the next-generation BTK inhibitor pirtobrutinib, could play a role earlier in the course of treatment.
- Currently, pirtobrutinib is used for patients whose CLL has already been treated with a BTK inhibitor. It belongs to a newer group of medications called non-covalent BTK inhibitors.
- Recent clinical trials have now shown that pirtobrutinib is also effective as an initial treatment for CLL, with results comparable to or better than some existing options. Researchers are also evaluating it in combination with other targeted therapies, such as venetoclax and anti-CD20 antibodies.
Even with these advances, researchers continue to look for ways to make treatments more effective, longer lasting, and easier to take. One area of active research is whether newer medications, including pirtobrutinib (brand name: Jaypirca), which is a targeted therapy known as a BTK inhibitor, could play a role earlier in the course of treatment.
Read MorePirtobrutinib’s Place in the Treatment Path
Currently, pirtobrutinib is used for patients whose CLL has already been treated with another BTK inhibitor, like acalabrutinib or zanubrutinib. It belongs to a newer group of medications called non-covalent BTK inhibitors. Unlike earlier BTK inhibitors, pirtobrutinib attaches to the BTK protein in a different way, allowing it to remain active even when some leukemia cells develop mutations that make older BTK inhibitors less effective.Because pirtobrutinib has shown promising results in previously treated patients, researchers have studied whether it could also benefit patients earlier in their treatment journey.
Recent clinical trials have now shown that pirtobrutinib is also effective as an initial treatment for CLL, with results comparable to or better than some existing options. Researchers are also evaluating it in combination with other targeted therapies, such as venetoclax and anti-CD20 antibodies.
“Right now, pirtobrutinib (Jayperka) has been approved for patients with relapse disease after the use of one of the BTK inhibitors that are covalently bound to the BTK. However, the only lingering hangup is with sequencing. We don’t know exactly what’s going to happen when you stop responding to pirtobrutinib (Jayperka),” Dr. Jacqueline Barrientos, Chief of Hematologic Malignancies at Mount Sinai Medical Center in Miami Beach, explains to SurvivorNet.
What to Know About BTK Inhibitors
The goal is to learn whether these combinations can produce deeper and longer-lasting responses, extend the time before CLL returns, improve long-term outcomes, or allow more patients to complete treatment after a fixed period.
An important question is where pirtobrutinib should fit in the sequence of CLL treatments. If it is used earlier, will it provide better long-term disease control? Could it replace the need for older BTK inhibitors in some patients? Or is it more valuable to reserve pirtobrutinib for later, after another BTK inhibitor stops working, so that patients have an additional effective treatment option available?
These questions are important because doctors want to use each therapy at the time when it provides the greatest benefit while preserving options for the future.
Researchers are also studying whether that approach improves outcomes compared with using currently established treatments first.
The Role of BCL-2 Inhibitors
Beyond pirtobrutinib, entirely new approaches to treating CLL are being explored including next-generation targeted therapies designed to overcome resistance and improve long-term disease control.
Researchers are studying newer BCL-2 inhibitors, bispecific antibodies, which help the immune system recognize and destroy leukemia cells, and CAR T-cell therapy, which uses a patient’s own immune cells that are modified to attack the cancer.
Scientists are also evaluating new combinations of targeted therapies and looking for better ways to personalize treatment — such as using highly sensitive tests to measure how much leukemia remains after treatment to help determine what comes next.
While many of these strategies are still being investigated, they represent exciting areas of research that may further expand treatment options in the future.
The outlook for people living with CLL continues to improve. As research advances, doctors hope to have even more ways to personalize treatment, overcome resistance, and help patients live longer with good quality of life. Ongoing research into pirtobrutinib and other next-generation targeted therapies is helping shape the future of CLL care and may provide more treatment options for patients in the years ahead.
Questions To Ask Your Doctor
- Should I consider a newer treatment option like pirtobrutinib?
- What are my options when treatment stops working?
- What side effects can I expect from targeted therapies?
- Are there any clinical trials testing new approaches I should consider?
Learn more about SurvivorNet's rigorous medical review process.
